on ABIVAX (EPA:ABVX)
Abivax unveils its objectives for 2026
The biotechnology company Abivax is projecting significant progress in 2026, focused on the development of its drug candidate, obefazimod. Obefazimod is currently in advanced clinical trials for the treatment of ulcerative colitis (UC). Market research predicts strong growth in this sector, potentially positioning obefazimod as a market leader.
Results from the ABTECT-UC trial, focused on UC, are expected by mid-2026, while the ENHANCE-CD study for Crohn's disease will unveil its first results by the end of 2026. In parallel, Abivax is presenting 22 abstracts at the ECCO congress, emphasizing the effect of obefazimod.
The company's financial visibility is assured until 2027, following the repayment of its debt. Abivax plans to submit a marketing authorization application in the United States at the end of 2026.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news